AXIM (AXIM Biotechnologies) Shareholder Yield % : -73.76% (As of Jun. 2025)


What is AXIM Biotechnologies Shareholder Yield %?

AXIM Biotechnologies AXIM +7.14% Shareholder Yield % is -73.76% as of Jun. 2025. The stock has 7 warning signs investors should review. Among 1,303 Biotechnology companies, AXIM Biotechnologies ranks worse than 92.56% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, AXIM Biotechnologies's Shareholder Yield % was -73.76%.


AXIM Biotechnologies  (OTCPK:AXIM) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


AXIM Biotechnologies Shareholder Yield % Related Terms


AXIM Biotechnologies Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for AXIM Biotechnologies's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AXIM Biotechnologies Shareholder Yield % Chart

AXIM Biotechnologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shareholder Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.84 -3.07 -18.79 -12.39 -232.22

AXIM Biotechnologies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -53.03 -36.88 -232.22 -27.63 -53.87

AXIM vs HEPA, SCNI, BZYR: Shareholder Yield % Comparison

For the Biotechnology subindustry, AXIM Biotechnologies's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AXIM Biotechnologies Shareholder Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AXIM Biotechnologies's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where AXIM Biotechnologies's Shareholder Yield % falls into.



AXIM Biotechnologies Shareholder Yield % Calculation

AXIM Biotechnologies's Shareholder Yield % for the quarter that ended in Jun. 2025 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+0.00 %+-53.87 %
=-53.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of -73.76% mean?
AXIM Biotechnologies (AXIM) has a Shareholder Yield % of -73.76% as of Jun. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on AXIM Biotechnologies and its competitors. According to the industry distribution chart, AXIM Biotechnologies ranks #1206 out of 1303 companies in the Biotechnology industry, placing it in the top 92.6%.
Is AXIM Biotechnologies' Shareholder Yield % too high?
AXIM Biotechnologies' current Shareholder Yield % is -73.76%. Based on the distribution chart, AXIM Biotechnologies ranks #1206 out of 1303 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does AXIM Biotechnologies' Shareholder Yield % compare to HEPA and SCNI?
According to the Biotechnology industry distribution chart, AXIM Biotechnologies ranks #1206 out of 1303 companies for Shareholder Yield %. This places AXIM Biotechnologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on AXIM Biotechnologies and its competitors. AXIM Biotechnologies's current Shareholder Yield % is -73.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AXIM Biotechnologies stock overvalued right now?
AXIM Biotechnologies (AXIM) has a current Shareholder Yield % of -73.76%. The current Shareholder Yield % is -73.76%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For AXIM Biotechnologies (AXIM), the current Shareholder Yield % is -73.76% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AXIM Biotechnologies Business Description

Address 6048 Cornerstone Court West, Suite E1, San Diego, CA, USA, 92121
AXIM Biotechnologies Inc is a integrated research and development company and developer of diagnostic healthcare solutions serving to enhance the health of people. The company focuses on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.